Clinical Utility of ctDNA in Escalating or De-escalating Melanoma Care

In an interview, Vincent Ma, MD, associate professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, explores the clinical utility of circulating tumor DNA (ctDNA) dynamics as a tool for interpreting ambiguous radiographic findings in patients with melanoma.

A significant challenge in immunotherapy is the phenomenon of pseudoprogression, where imaging suggests disease growth due to immune-related inflammatory changes rather than actual tumor proliferation. Ma notes that in a subset of patients that he studied where imaging indicated progression, a concurrent decrease in ctDNA levels from baseline at 3 to 4 weeks accurately predicted that the radiographic changes were inflammatory. This suggests that ctDNA dynamics can serve as a critical differentiator between true disease progression and immune-mediated responses.

Current Standard vs Future Applications

Although Ma acknowledges that radiographic imaging remains the current standard of care for monitoring treatment, he emphasizes that ctDNA offers a “window into treatment efficacy” weeks before traditional scans can provide a clear picture. Currently viewed primarily as a prognostic biomarker, the potential applications for ctDNA are expanding.

An early increase in ctDNA could serve as a trigger for prompt treatment escalation, earlier clinical trial enrollment, or more frequent radiographic monitoring. Conversely, early ctDNA clearance or a significant decrease provides a rationale for continuing current therapy, offering reassurance during equivocal imaging results, and potentially informing future de-escalation strategies.

The Path Toward Clinical Integration

The transition from a prognostic tool to a predictive one that guides active treatment adaptation requires further validation. Ma concludes that although the retrospective data is compelling, prospective clinical trials are essential. These trials will determine if adapting treatment based on ctDNA signals can directly improve patient survival and quality of life. By integrating molecular kinetics with traditional imaging, clinicians may soon be able to personalize melanoma therapy with much higher precision.